aromasil has been researched along with Local Neoplasm Recurrence in 53 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 19 (35.85) | 29.6817 |
| 2010's | 27 (50.94) | 24.3611 |
| 2020's | 7 (13.21) | 2.80 |
| Authors | Studies |
|---|---|
| Aruga, T; Iwasa, T; Iwata, H; Kaneda, A; Kaneko, K; Kawabata, A; Kobayashi, K; Lee, MJ; Masuda, N; Nakamura, R; Nishimura, Y; Saji, S; Seike, T; Tamura, K; Tokunaga, E; Trepel, JB; Tsurutani, J; Yamamoto, Y; Yamashita, T; Yonemori, K; Yuno, A | 1 |
| Coates, AS; Colleoni, M; Di Leo, A; Fleming, GF; Francis, PA; Gelber, RD; Goldhirsch, A; Gómez, HL; Láng, I; Pagani, O; Pinotti, G; Regan, MM; Tondini, C; Viale, G; Walley, BA | 1 |
| Francis, PA | 1 |
| Petit, T | 1 |
| Bartlett, JMS; Blok, EJ; Duijm-de Carpentier, M; Hasenburg, A; Hozumi, Y; Kroep, JR; Liefers, GJ; Markopoulos, CJ; Meershoek-Klein Kranenbarg, E; Noordhoek, I; Paridaens, R; Portielje, JEA; Putter, H; Rea, DW; Rutgers, EJT; Seynaeve, C; van de Velde, CJH; Vannetzel, JM | 1 |
| Cao, Y; Ding, J; Fu, W; Guo, Y; Jiang, X; Li, K | 1 |
| Ahn, HK; Im, SA; Jung, KH; Kang, SY; Kim, GM; Kim, JH; Lee, J; Park, IH; Park, YH | 1 |
| Adachi, M; Amemiya, T; Hata, H; Hayashi, N; Kashiwabara, K; Kikawa, Y; Kondo, N; Mitsunaga, S; Mukai, H; Naito, M; Nakagami, K; Nakatsukasa, K; Niikura, N; Ota, Y; Shibuya, Y; Taniike, N; Umeda, M; Watanabe, KI; Yamanaka, T; Yamashita, T | 1 |
| Abdel-Razeq, H; Adhav, A; Aksoy, S; Bowles, J; Chae, Y; Chang, YC; Cinkir, HY; Im, SA; Im, YH; Jeong, J; Karabulut, B; Kim, SB; Lee, KS; Park, BW; Slimane, K; Xue, H | 1 |
| Bartlett, JMS; Bliss, JM; Cheang, MCU; Coombes, RC; Jassem, J; Lønning, PE; Morden, J; Palmieri, C; Porta, N; Rasmussen, BB; Shaaban, A; Speirs, V; van De Velde, CJ; Verhoeven, D; Viale, G | 1 |
| Bellet, M; Bonnefoi, HR; Buchholz, S; Burstein, HJ; Ciruelos, E; Climent, MA; Coates, AS; Coleman, R; Colleoni, M; Davidson, NE; Debled, M; Di Leo, A; Fleming, GF; Francis, PA; Gelber, RD; Geyer, CE; Goetz, MP; Goldhirsch, A; Gómez, HL; Ingle, JN; Láng, I; Maibach, R; Martino, S; Pagani, O; Pavesi, L; Pinotti, G; Puglisi, F; Rabaglio-Poretti, M; Regan, MM; Ruepp, B; Ruhstaller, T; Spazzapan, S; Stearns, V; Tondini, C; Walley, BA; Winer, EP | 1 |
| Barbolini, M; Bettelli, S; Caprera, C; Cascinu, S; Conte, PF; Filieri, ME; Guaitoli, G; Kaleci, S; Maiorana, A; Manfredini, S; Moscetti, L; Nasso, C; Omarini, C; Piacentini, F | 1 |
| Cheng, Y; Cristofanilli, M; Cui, S; Feng, J; Gao, J; Geng, C; Gu, K; Hu, X; Jiang, Z; Li, W; Liu, T; Lu, X; Ning, Z; Ouyang, Q; Ouyang, T; Pan, Y; Sun, T; Sun, Y; Tong, Z; Wang, H; Wang, S; Wang, X; Yin, Y; Zhang, Q | 1 |
| Conforti, F; Pala, L | 1 |
| Cruickshank, S; Ismail-Khan, RR; Klein, PM; Lee, MJ; Lichinitser, M; Melichar, B; Miller, KD; Munster, PN; Trepel, JB; Yardley, DA | 1 |
| Kuranishi, F; Ohno, T | 1 |
| Bastiaannet, E; Hasenburg, A; Hozumi, Y; Jones, SE; Liefers, GJ; Marijnen, CA; Markopoulos, C; Paridaens, R; Putter, H; Rea, D; Scholten, AN; Seynaeve, C; van de Velde, CJ; van Hezewijk, M | 1 |
| Aogi, K; Hisamatsu, K; Iwata, H; Kuroi, K; Masuda, N; Ohno, S; Saji, S; Sasano, H; Sato, N; Takei, H; Toi, M; Ueno, T; Yamamoto, Y; Yamanaka, T; Yamashita, H | 1 |
| Baselga, J; Bourgeois, H; Burris, HA; Campone, M; Csöszi, T; Dakhil, S; Gnant, M; Gonzalez Martin, A; Heng, D; Hortobagyi, GN; Ito, Y; Noguchi, S; Osborne, K; Panneerselvam, A; Piccart, M; Pritchard, KI; Puttawibul, P; Rugo, HS; Sahmoud, T; Srimuninnimit, V; Taran, T | 1 |
| Bachelot, T; Duffy, S; Fleetwood, K; Glanville, J; Jerusalem, G; McCool, R; Varley, D; Zhang, J | 1 |
| Beck, JT; Brechenmacher, T; Campone, M; Dakhil, S; Deleu, I; Douma, S; El-Hashimy, M; Geberth, M; Hart, L; Heng, DY; Hortobagyi, GN; Lebrun, F; Masuda, N; Melichar, B; Nunzi, M; Piccart, M; Pistilli, B; Ringeisen, F; Rugo, HS | 1 |
| Aavall-Lundqvist, E; Boman, K; Christensen, RD; Kristensen, GB; Lindemann, K; Malander, S; Mirza, MR; Nordstrøm, B; Rosenberg, P; Vergote, I | 1 |
| A'Hern, R; Afentakis, M; Arnedos, M; Dowsett, M; Drury, S; Hills, M; Reis-Filho, JS; Salter, J; Smith, IE | 1 |
| Bastiaannet, E; De Craen, AJ; de Glas, NA; de Haes, HJ; Fontein, DB; Liefers, GJ; Nortier, HJ; Pijpe, A; van de Velde, CJ; van Leeuwen, FE | 1 |
| Allevi, G; Andreis, D; Bottini, A; Buffa, FM; Byrne, D; Cummings, M; Deb, S; Ferrero, G; Fox, SB; Generali, D; Harris, AL; Lakhani, SR; Martinotti, M; Reid, LE; Taylor, M | 1 |
| Beex, LV; Duijm-de Carpentier, M; Lardenoije, S; Nortier, JW; Putter, H; Seynaeve, C; Sramek, A; van de Velde, CJ; van Nes, JG; Van Rongen, I; Zonderland, HM | 1 |
| Bartlett, JM; Bastiaannet, E; Charehbili, A; Engels, CC; Kuppen, PJ; Liefers, GJ; Putter, H; Sajet, A; Seynaeve, C; Smit, VT; van de Velde, CJ; van Vlierberghe, RL; van Vliet, EA | 1 |
| Ditzel, HJ; Elias, D; Knoop, AS; Lykkesfeldt, AE; Lyng, MB; Lænkholm, AV; Thomsen, KG; Vever, H | 1 |
| Coates, AS; Colleoni, M; Fleming, GF; Francis, PA; Gelber, RD; Goldhirsch, A; Gómez, HL; Láng, I; Pagani, O; Pinotti, G; Price, KN; Regan, MM; Tondini, C; Viale, G; Walley, BA | 1 |
| Bianchetti, S; Camozzi, M; Ciruelos, EM; Conte, P; Gavila, JG; Generali, D; Jerusalem, G; Lang, I; Lorizzo, K; Mardiak, J; Mariani, G; Martin, M; Michelotti, A; Montemurro, F; Naume, B; Neven, P; Simoncini, E; Tjan-Heijnen, VC | 1 |
| Allred, DC; Babiera, G; Barnes, M; Brink, A; Budd, GT; Carey, L; Creighton, CJ; Crouch, E; Dayao, Z; DeSchryver, K; Dowsett, M; Ellis, MJ; Esserman, L; Goncalves, R; Guenther, JM; Hoog, J; Hunt, K; Leitch, M; Luo, J; Ma, CX; Olson, JA; Ota, D; Pluard, T; Sanati, S; Silverman, P; Suman, VJ; Tao, Y; Unzeitig, G; Watson, M; Whitworth, P; Winer, E | 1 |
| Nagykálnai, T | 1 |
| Dziadziuszko, R; Jassem, J; Orłowska-Kunikowska, E; Senkus-Konefka, E | 1 |
| Aogi, K; Hara, F; Kiyoto, S; Osumi, S; Takabatake, D; Takashima, S | 1 |
| Doughty, JC | 1 |
| Brueggemeier, RW; Layman, RM; Lehman, AM; Lustberg, MB; Mrozek, E; Povoski, SP; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shiels, DR; Sugimoto, Y; Zhao, W; Ziegler, RM | 1 |
| Bartlett, JMS; Dirix, LY; Fontein, DBY; Gelderblom, H; Guchelaar, HJ; Hille, ETM; Houtsma, D; Meershoek-Klein Kranenbarg, E; Nortier, JWR; Paridaens, R; Putter, H; Seynaeve, C; van de Velde, CJH | 1 |
| Buzdar, AU | 1 |
| Bhide, SA; Rea, DW | 1 |
| Aebi, S; Baumann, ChK | 1 |
| Jakesz, R | 1 |
| Dewar, R; Rayson, D; Skedgel, C; Younis, T | 1 |
| Holmberg, S; Jönsson, L; Lundkvist, J; Wilking, N | 1 |
| Alvarez, I; Andersen, J; Bajetta, E; Bertelli, G; Bliss, JM; Bogle, RG; Carpentieri, M; Castiglione, M; Coates, AS; Cocconi, G; Colajori, E; Coleman, RE; Coombes, RC; Del Mastro, L; Delozier, T; Diedrich, K; Dodwell, D; Fallowfield, LJ; Forbes, J; Hall, E; Holmberg, SB; Ireland, E; Jassem, J; Jones, SE; Kilburn, LS; Lønning, PE; Mickiewicz, E; Ortmann, O; Paridaens, R; Snowdon, CF; Stewart, A; Stuart, N; Subar, M; Van de Velde, CJ | 1 |
| Aapro, M; Cannon, H; Georgiou, V; Leto di Priolo, S; Wengström, Y | 1 |
| Mittmann, N; Risebrough, NA; Trudeau, M; Verma, S | 1 |
| Carroll, C; De Nigris, E; Hind, D; Simpson, E; Ward, S; Wyld, L | 1 |
| Amant, F; Bines, J; Brufsky, A; Buzdar, A; Chia, S; Federico, M; Fein, L; Gradishar, W; Lowe, E; Mauriac, L; Piccart, M; Possinger, K; Rennie, P; Robertson, JF; Romieu, G; Sapunar, F | 1 |
| Pennery, E | 1 |
| Gligorov, J; Nabholtz, JM | 1 |
| Arkhipov, A; Bajetta, E; Cervek, J; di Salle, E; Dirix, LY; Dugardyn, JL; Fein, LE; Fowst, C; Jones, SE; Kaufmann, M; Massimini, G; Mennel, RG; Miller, LL; Nasurdi, C; Piscitelli, G; Polli, A; Zilembo, N | 1 |
9 review(s) available for aromasil and Local Neoplasm Recurrence
| Article | Year |
|---|---|
[Endocrine adjuvant treatment specific features for young breast cancer women].
Topics: Adult; Amenorrhea; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Goserelin; Humans; Luteolytic Agents; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Time Factors; Triptorelin Pamoate | 2019 |
Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Estradiol; Everolimus; Female; Fulvestrant; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sirolimus; Treatment Outcome | 2014 |
[Adjuvant endocrine therapy in postmenopausal hormone-sensitive breast cancer: to start, to switch or to extend?].
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Resistance, Neoplasm; Estrogen Receptor Modulators; Female; Humans; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quality of Life; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Tamoxifen; Treatment Outcome; Triazoles | 2008 |
When to start an aromatase inhibitor: now or later?
Topics: Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Tamoxifen; Triazoles | 2011 |
Aromatase inhibitors in breast cancer therapy.
Topics: Anastrozole; Androstadienes; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Enzyme Inhibitors; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Triazoles | 2003 |
[Aromatase inhibitors in the adjuvant therapy of breast carcinomas].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Patient Care Management; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tamoxifen; Treatment Outcome; Triazoles | 2004 |
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Drug Administration Schedule; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Quality-Adjusted Life Years; Survival Analysis; Tamoxifen; Time Factors; Triazoles | 2007 |
The role of endocrine therapies in reducing risk of recurrence in postmenopausal women with hormone receptor-positive breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Nurse Clinicians; Nurse Practitioners; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Postmenopause; Receptors, Estrogen; Risk Factors; Tamoxifen; Time Factors; Treatment Outcome; Triazoles | 2008 |
The emerging role of aromatase inhibitors in the adjuvant management of breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Therapy, Combination; Humans; Letrozole; Neoplasm Recurrence, Local; Nitriles; Randomized Controlled Trials as Topic; Tamoxifen; Treatment Outcome; Triazoles | 2006 |
22 trial(s) available for aromasil and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Estrogen Receptor alpha; Female; Humans; Lysine; Neoplasm Recurrence, Local; Receptors, Estrogen | 2023 |
Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Case-Control Studies; Everolimus; Female; Follow-Up Studies; Humans; Japan; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oral Health; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Stomatitis; Survival Rate | 2021 |
Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES.
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Time Factors | 2018 |
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Premenopause; Receptor, ErbB-2; Tamoxifen; Young Adult | 2018 |
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aminopyridines; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Breast Neoplasms; Double-Blind Method; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Salvage Therapy; Survival Rate; Treatment Outcome | 2019 |
Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromata
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzamides; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Postmenopause; Pyridines; Receptors, Estrogen | 2013 |
Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; International Cooperation; Mastectomy, Segmental; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Postmenopause; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Reference Values; Risk Assessment; Survival Analysis; Tamoxifen; Treatment Outcome | 2013 |
Evaluating the 21-gene assay Recurrence Score® as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer.
Topics: Aged; Androstadienes; Breast Neoplasms; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Receptor, ErbB-2; Receptors, Progesterone; Treatment Outcome | 2014 |
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; International Agencies; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Safety; Sirolimus; Survival Rate | 2013 |
Everolimus plus exemestane as first-line therapy in HR⁺, HER2⁻ advanced breast cancer in BOLERO-2.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Everolimus; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Receptors, Estrogen; Receptors, Progesterone; Sirolimus | 2014 |
Examestane in advanced or recurrent endometrial carcinoma: a prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO).
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Denmark; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Norway; Prospective Studies; Societies, Medical; Sweden | 2014 |
Physical activity and survival of postmenopausal, hormone receptor-positive breast cancer patients: results of the Tamoxifen Exemestane Adjuvant Multicenter Lifestyle study.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Combined Modality Therapy; Exercise; Female; Follow-Up Studies; Humans; Life Style; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Postmenopause; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tamoxifen | 2014 |
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Celecoxib; Cohort Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prognosis; Pyrazoles; Sulfonamides; Survival Analysis | 2014 |
Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysis.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents, Hormonal; Breast Density; Breast Neoplasms; Chemotherapy, Adjuvant; Estrogen Antagonists; Female; Humans; Mammary Glands, Human; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Radiography; Tamoxifen; Treatment Outcome | 2015 |
The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Forkhead Transcription Factors; Histocompatibility Antigens Class I; HLA-E Antigens; HLA-G Antigens; Humans; Immunophenotyping; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Prognosis; Receptors, Estrogen; T-Lymphocytes, Regulatory; Tamoxifen | 2015 |
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, e
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Everolimus; Female; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus | 2016 |
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Decision-Making; Female; Follow-Up Studies; Humans; Ki-67 Antigen; Letrozole; Middle Aged; Mitotic Index; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Transcriptome; Triazoles | 2017 |
Phase II trial of neoadjuvant exemestane in combination with celecoxib in postmenopausal women who have breast cancer.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lobular; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Postmenopause; Pyrazoles; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sulfonamides; Survival Rate; Treatment Outcome | 2011 |
Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden.
Topics: Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Neoplasm Recurrence, Local; Quality of Life; Sweden; Tamoxifen | 2007 |
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
Topics: Aged; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Selective Estrogen Receptor Modulators; Survival Analysis; Tamoxifen | 2007 |
Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; Estradiol; Female; Fulvestrant; Humans; Kaplan-Meier Estimate; Neoplasm Recurrence, Local; Placebos; Postmenopause; Quality of Life; Receptors, Estrogen | 2008 |
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Progression; Double-Blind Method; Female; Humans; Megestrol Acetate; Middle Aged; Neoplasm Recurrence, Local; Pain; Postmenopause; Quality of Life; Survival Analysis; Tamoxifen; Treatment Outcome | 2000 |
22 other study(ies) available for aromasil and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Female; Humans; Neoplasm Recurrence, Local; Ovariectomy; Ovary; Premenopause; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Triptorelin Pamoate | 2020 |
Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration.
Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovary; Premenopause; Randomized Controlled Trials as Topic; Risk Assessment; Tamoxifen; Time Factors; Young Adult | 2019 |
Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.
Topics: Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cohort Studies; Female; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Receptors, Estrogen; Reproducibility of Results; Risk Assessment; Tamoxifen | 2020 |
Concomitant fulvestrant with reirradiation for unresectable locoregional recurrent estrogen receptor positive (ER+) breast cancer: A case report and narrative review.
Topics: Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Lymphatic Metastasis; Mastectomy, Modified Radical; Middle Aged; Narrative Medicine; Neoplasm Recurrence, Local; Re-Irradiation; Receptors, Estrogen | 2020 |
Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL).
Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Female; Humans; Mastectomy; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Piperazines; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2021 |
Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Asia; Breast Neoplasms; Everolimus; Female; Humans; Neoplasm Recurrence, Local; Postmenopause; Receptor, ErbB-2; Sirolimus | 2021 |
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; DNA Mutational Analysis; Everolimus; Female; Genes, Neoplasm; Humans; Middle Aged; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Prospective Studies; Retrospective Studies; Sirolimus | 2018 |
Exemestane Plus Ovarian Function Suppression Is the Best Adjuvant Treatment of Premenopausal Women With Endocrine-Responsive Breast Cancer at Higher Risk of Relapse and With HER2-Negative Tumors.
Topics: Androstadienes; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Premenopause | 2019 |
Eradication of breast cancer with bone metastasis by autologous formalin-fixed tumor vaccine (AFTV) combined with palliative radiation therapy and adjuvant chemotherapy: a case report.
Topics: Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Bone Neoplasms; Breast Neoplasms; Cancer Vaccines; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Diphosphonates; Epirubicin; Female; Fixatives; Fluorouracil; Formaldehyde; Humans; Imidazoles; Magnetic Resonance Imaging; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prognosis; Radiotherapy Dosage; Tomography, Emission-Computed, Single-Photon; Triazoles; Zoledronic Acid | 2013 |
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Androstadienes; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Insulin Receptor Substrate Proteins; Ki-67 Antigen; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; PTEN Phosphohydrolase; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Stathmin; Tamoxifen; Triazoles | 2014 |
Gene expression alterations associated with outcome in aromatase inhibitor-treated ER+ early-stage breast cancer patients.
Topics: Aged; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Eye Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Peptides; Receptors, Estrogen; Retrospective Studies; RGS Proteins; Transcription Factors; Treatment Outcome; Trefoil Factor-3; Triazoles | 2015 |
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.
Topics: Adult; Aged; Androstadienes; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovary; Proportional Hazards Models; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen | 2016 |
Exacerbation of diabetes related to exemestane treatment.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Blood Glucose; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Humans; Insulin Resistance; Middle Aged; Neoplasm Recurrence, Local; Thoracic Wall | 2008 |
[A case of recurrent breast cancer with extensive liver metastasis successfully treated with endocrine therapy].
Topics: Androstadienes; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Letrozole; Liver Neoplasms; Medroxyprogesterone; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Toremifene; Triazoles | 2009 |
Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Treatment Outcome | 2012 |
Metastatic breast cancer response after Exemestane withdrawal: a case report.
Topics: Adult; Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Enzyme Inhibitors; Female; Humans; Neoplasm Recurrence, Local; Remission, Spontaneous | 2004 |
Tamoxifen shuffle.
Topics: Androstadienes; Antineoplastic Agents; Breast Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Tamoxifen | 2004 |
[New strategies against breast carcinoma. To outwit the resistance tendency of tumor cells].
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Female; Fulvestrant; Humans; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Nitriles; Tamoxifen; Time Factors; Triazoles | 2005 |
Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Disease-Free Survival; Drug Administration Schedule; Drug Costs; Female; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Recurrence, Local; Nitriles; Postmenopause; Quality-Adjusted Life Years; Tamoxifen; Treatment Outcome; Triazoles; United States | 2007 |
Cancer: some reasons to be hopeful.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Neoplasm Recurrence, Local; Tamoxifen | 2007 |
Patients' knowledge and experience of adjuvant endocrine therapy for early breast cancer: a European study.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Communication Barriers; Decision Making; Europe; Female; Health Knowledge, Attitudes, Practice; Humans; Letrozole; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Selective Estrogen Receptor Modulators; Surveys and Questionnaires; Tamoxifen; Triazoles | 2007 |
Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer.
Topics: Androstadienes; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Cost-Benefit Analysis; Drug Costs; Female; Humans; Markov Chains; Middle Aged; Neoplasm Recurrence, Local; Postmenopause; Quality-Adjusted Life Years; SEER Program; Selective Estrogen Receptor Modulators; Sensitivity and Specificity; Survival Rate; Tamoxifen | 2007 |